Introduction
Preclinical development of novel therapies for leukemia requires in vivo models to assess drug pharmacology, immune response and preliminary therapeutic index. Particularly with the emergence of agents targeted to human differentiation antigens, receptors and signal transduction pathway elements, there is a need for a reproducible, established human differentiated myeloid leukemia model in rodents.
Methods currently available for engraftment of patient AML blasts include implantation of patient blasts into irradiated SCID or NOD/SCID mice. [1] [2] [3] [4] [5] In some cases, improved growth has been observed in mice receiving regular intraperitoneal injections of growth factors (PIXY321 and human mast-cell growth factor). 6 In other cases, AML growth only occurred in human fetal bone marrow subcutaneous implants in SCID mice. 7 In most cases, engraftment was transient and subsequent in vivo passage was not shown. Attempts to grow human AML cells in NOD/SCID mice have also shown in 60% of cases that the phenotype of the AML graft showed major changes after outgrowth in NOD/SCID. number of investigators have examined the in vivo growth potential of AML cell lines. Poorly differentiated cytokineindependent cell lines propagated well in cyclophosphamidetreated or irradiated SCID mice. 2, 5, 9 Cytokine-dependent, differentiated AML cell lines only grew in cyclophosphamide treated and irradiated nude mice when the cells were retrovirally infected to express growth factors interleukin-3 (IL3) or granulocyte-macrophage colony-stimulating factor (GM-CSF). 10 Using a similar approach transgenic nude mice have been developed which overexpress human IL3 or GM-CSF. These animals yield subcutaneous tumors after implantation with the cytokine-dependent TF-1 AML cells. 11, 12 While these approaches have been successful, they result in receptor saturation and engagement. Therapeutics which target the IL3 or GM-CSF receptor may be blocked by the autocrine or paracrine cytokines.
We sought to establish an in vivo model with differentiated human AML blasts expressing unoccupied growth factor receptors. Since cytokine receptor-mediated signaling pathways may be critical for blast survival and proliferation, we chose to transfect genes which would provide constitutive signaling through the cytokine receptor pathway bypassing the cytokine-cell surface receptor activation step. We now report the in vivo growth characteristics and cytokine receptor properties of a series of these cell lines.
Materials and methods

Cell lines
The human cytokine-dependent TF-1 cells were grown in RPMI 1640 (Life Technologies, Gaithersburg, MD, USA) + 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and supplemented with 1 ng/ml human GM-CSF (Immunex, Seattle, WA, USA). 13 TF-1 cells were retrovirally infected as previously described to yield transfectants expressing v-Src, vHa-Ras, BCR-ABL, and activated Raf-1 (⌬Raf-1) as previously described.
14,15 8A#2 cells were TF-1 cells transfected with the genomic GM-CSF gene linked to the Moloney murine leukemia virus long terminal repeat. 16 The Tumor-1 cell line was derived from TF-1 cells collected from cells propagated as a subcutaneous tumor in nude mice. 16 Table 1 details all the cell lines used. Cell lines, other than wild-type TF-1, were grown in RPMI 1640 + 10% FBS.
IL3 receptor densities
Cell binding of 125 I-labeled IL3 receptor agonist SC-65461 (Pharmacia, St Louis, MO, USA) in the presence and absence of unlabeled human IL-3 (SC-50341, Pharmacia) was measured as previously described. 17 Nonlinear regression analysis using GraphPad Prism (GraphPad Software) was used to calculate high and low receptor affinities and densities.
DT 388 IL3 sensitivities
Cells were incubated with varying concentrations of DT 388 IL3 and 3 H-thymidine incorporation was measured after 48 h as previously described. 18 The calculated IC 50 s were the concentrations of fusion protein that inhibited thymidine incorporation by 50% compared to control wells.
Cytogenetics
For routine cytogenetic studies, cultured cells were exposed to 10 g/ml of colcemid for 20 min, then spun down at 1000 g for 8 min. The cell pellet was resuspended in a hypotonic solution (0.075 m KCl) for 10 min. The spun down cells were fixed in 3:1 methanol:glacial acetic acid three times prior to slide preparation. Metaphase slides were banded using routine GTG-banding. 19 Standard ISCN nomenclature was used to interpret the M-FISH/G-banded metaphases.
For multi-color FISH, slides were prepared and then pretreated with RNase (10 mg/ml in 2 × SSC at 37°C) for 30 min followed by 10% pepsin in 0.01 N HCl for 5 min. 20 After washing in PBS, slides were dehydrated in an ethanol series and allowed to air dry. Slides were denatured in 70% formamide/2 × SSC at 72°C for 1 to 3 min and then dehydrated in a cold ethanol series (70%, 80% and 100%) for 1 min. Vysis Spectrya Vysion M-FISH probe (10 l) was denatured in a 72°C water bath for 5 min and then applied to a heated slide (42°C). Hybridization was allowed to proceed for 48 h in a humid chamber. Slides were post-washed according to the manufacturer's instructions: 0.4 × SSC/0.3% NP-40 at 72°C for 2 min followed by 5 to 30 s rinses in 2 × SSC/0.1% NP-40 at room temperature. Slides were air dried and counterstained with DAPI II (Vysis, 125 ng/ml in anti-fade mounting solution). Analysis of the M-FISH chromosome metaphases was completed using the SpectraVysion Imaging System. This system's software captures each of six different fluorescent planes of a single metaphase spread allowing for the identity of each of the 24 differently fluorescent tagged Leukemia probes that have hybridized to each chromosome. A karyotype is then generated based on the fluorescent labeling of the individual chromosomes. In addition, the software also generates DAPI bands permitting the chromosomes to be arranged in a standard karyotype.
Animals
Balb-c-SCID/SCID mice (males and females; age 4-6 weeks) were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and maintained in micro-isolator cages housed in laminar flow cubicles in a positive pressure room. The temperature of the room ranged from 22 to 25°C. The water was autoclaved and provided ad libitum. The food was irradiated and provided ad libitum. The mice were allowed to adjust to their new environment for 1 week. The mice were then irradiated with 300 cGy total body irradiation to diminish natural killer cell activity. 21 After 24 h of observation, the mice were injected i.v. via tail vein with 2 × 10 7 TF-1 or modified TF-1 cells diluted in 0.2 ml of phosphate buffered saline (BioWhittaker, Walkersville, MD, USA) with 1% bovine serum albumin (Sigma, St Louis, MO, USA). After completion of all injections, cells from residual syringes were Ͼ90% viable by Trypan Blue exclusion. A total of 119 mice were used. The mice were examined daily for overall activity and for the presence of masses. Moribund mice were sacrificed.
Autopsies
Moribund SCID mice were sacrificed painlessly by standard CO 2 asphyxiation, consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. Samples from major organs and abdominal masses were removed, fixed in 4% buffered formaldehyde, dehydrated and embedded in paraffin. Sections were stained with hematoloxylin and eosin and examined under the microscope.
In some animals, abdominal masses were resected, minced, separated by use of a cell strainer (Falcon 2340) and tested for the number of IL3 receptors, DT 388 IL3 sensitivity, and cytogenetics as described above.
Statistical analysis
Survival was analyzed by the Kaplan-Meier method and mean survival time and standard deviation of the survival time was determined using GraphPad Prism software. For comparison of the number of IL3 receptors, dissociation constants, and IC 50 s, a Mann-Whitney test was utilized. The Mantel-Cox (logrank) test was used for comparison of survival between the groups.
Results
All of the TF-1 cell lines expressed high and low affinity IL3 receptors and were sensitive to DT 388 IL3 ( Table 2 ). The TF-1 cell lines showed a complex but reproducible set of cytogenetic abnormalities (Figure 1) . A final karyotype was generated based on the GTG banded metaphase chromosome spreads in conjunction with the M-FISH analysis. The cytogenetic nomenclature for the cell line was based on the G-banded karyotype (n = 20) and M-FISH chromosome preparations (n = 10). Exact breakpoints/chromosomal regions of some of the derived chromosomes could not be determined with certainty using G-banding and M-FISH and are so indicated within the nomenclature. The karyotype is as follows: 54,XY, der(1)(1qter-Ͼp22::5?-Ͼ5?::1?-Ͼ1?::5?-Ͼ5?::8q13-Ͼ8qter),del (1)(q21),der(2)(2pter-Ͼ2q33::15q15-Ͼq24::Xq26-ϾXqter),-3,der (3)(3q21-Ͼ3p25::Xq26-ϾXqter),der(6)t(6;14)(p21.2;?),der (7) the different TF-1 lines (Table 3) . Cells overexpressing v-Src or human GM-CSF propagated in mice. In addition, cells passaged as subcutaneous tumors in nude mice grew after intravenous injection in SCID mice. In contrast, cells transfected with v-Ha-Ras, BCR-ABL, or activated Raf-1 grew poorly or were completely unable to grow after intravenous injection into SCID mice. SCID mice inoculated with TF/v-Src cells intravenously died of progressive disease with a mean survival of 34 ± 10 days (Figure 3 ). Mice given intraperitoneal inoculations of TF/v-Src died of disseminated leukemia with a mean survival of 24 ± 3 days. Histopathology showed abdominal masses along the path of the vena cava and the thoracic aorta, and infiltration of the liver, kidney, adrenals, skeletal muscle, stomach and pancreas ( Figure 2 ). Resected abdominal masses were assayed for IL3 receptors, DT 388 IL3 sensitivity and cytogenetics. Results closely matched those with cells prior to inoculation into SCID mice (Table 2 and Figure 1 ).
Leukemia
Figure 2
Histopathology of SCID mice moribund with progressive leukemia after intravenous inoculation of 20 million TF/v-Src cells. Hematoxylin and eosin stained 6 micron paraffin sections of indicated tissues. Leukemia infiltrates are shown by arrows.
Figure 3
Survival of SCID mice after i.v. injection of 2 × 10 7 TF/vSrc cells on day 1. GraphPad Prism software was used to generate the survival curve. Animals censored at time of death for nonleukemic causes confirmed by histopathology.
Discussion
To establish an in vivo model of a differentiated AML, we modified the TF-1 cytokine-dependent cell line. Cell lines expressing activated oncogenes or the GM-CSF growth factor were prepared. These AML cells became cytokine-indeLeukemia pendent but retained evidence of differentiation with IL3 receptors and DT 388 IL3 sensitivity. We also selected a cell line which propagated in nude mice. These cells had also lost cytokine-dependence but retained IL3 receptors. Karyotypic analysis suggested no gross changes in genetic material between these cell lines.
We next sought to determine the in vivo growth characteristics of these cells in immunocompromised mice. The TF-1 cells transformed with v-Src grew best in mice. v-Src is a nonreceptor tyrosine kinase which may stimulate cytokine-independent proliferation and cell survival by activating Ras, and, subsequently, the Raf-MAPK signaling pathway. 21 Interestingly, v-Src-transformed cells grew better in vivo than v-HaRas, activated Raf or BCR/ABL transformed cells. The observed difference in tumorigenicity between v-Src, v-HaRas and activated Raf is not likely due to a difference in growth rate as the cell lines displayed similar growth characteristics in vitro. 15 Moreover, the differences in tumor formation between v-Src, v-Ha-Ras and activated Raf was not likely due to higher levels of autocrine cytokine production as the v-Src transformed cells produced lower levels of autocrine GM-CSF than the activated Raf-transformed cells. The enhanced in vivo growth may be due to the position of Src in signal transduction pathways as it can activate more downstream targets than Raf. Some v-Src transformed cells display constitutive activation of Jak and STAT proteins. [22] [23] [24] [25] It is conceivable that v-Src induces the activation of specific signalling molecules better than v-Ha-Ras or activated Raf. Moreover, v-Src may activate the phosphotidyl inositol-3 kinase (PI3K)/AKT survival pathway. Similar tumor growth in vivo was achieved by autocrine expression of GM-CSF in these cells. A number of investigators have postulated autocrine loops involving GM-CSF and GM-CSF receptors in the genesis of AML. 21, 26 GM-CSF likely stimulates non-receptor tyrosine kinases to also activate the Jak kinase and STAT transcription factors, as well as the Ras and the Raf-MAPK signaling pathway. 21 Moreover, GM-CSF stimulates the PI3K/AKT survival pathway. The mechanism for the cytokine independence of the nude mouse tumor derived Tumor-1 cell line is currently unknown.
Importantly, all these cell lines retained differentiated phenotypes with continued expression of IL3 receptors and DT 388 IL3 sensitivity. Further, the stability of the cytogenetic abnormalities of the TF/v-SRC cell line contrasts with the alterations in phenotypes observed with previous attempts to grow human AML cells in NOD/SCID mice. 8 With the invasive, aggressive nature of the disease in the TF/v-Src leukemic mice and their retention of a differentiated AML phenotype, this model should serve as an excellent assay system to evaluate the in vivo anti-leukemic efficacy of a number of human IL3 receptor targeted therapeutics including DT 388 IL3 fusion protein 27 and IL3 receptor agonists and antagonists. 28 
